Podcasts about Bladder cancer

In this powerful episode of Bladder Cancer Matters, Rick Bangs sits down with Mike Vasallo, a high school assistant principal diagnosed with early-onset bladder cancer at 46 who turned fear and uncertainty into purpose. Mike shares his raw, honest journey through diagnosis, treatment and recovery—and how finding community, asking for help and leaning into advocacy changed everything. He also explains how he uses humor, data and even TikTok trends to educate and reach people who might never otherwise learn about bladder cancer. The conversation dives into the emotional toll of cancer, the realities of treatment and why speaking up can make a life-changing difference for patients and caregivers alike. It's an inspiring, practical and deeply human story about resilience, connection and using your voice to help others feel less alone.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bladder Cancer⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert pathology reviews and the evolving landscape of neoadjuvant therapy in this field.

Todd Harris, CEO and Co-Founder of Tyra Biosciences, is focused on developing a selective inhibitor for FGFR3, a protein implicated in bladder cancer and childhood dwarfism. The company has developed the SNAP discovery platform to accelerate structure-based drug design targeting this specific protein, while avoiding effects on related proteins to minimize significant side effects. Their lead drug candidate has the potential to become a primary well-tolerated oral monotherapy, shifting the treatment paradigm for cancer patients to prevent recurrence and for children to allow for more typical bone growth. Todd explains, "We are taking a novel step to a set of conditions, genetic conditions in FGFR3 biology that have long been known, that others have attempted to address, but where the underlying chemistry hasn't had the necessary selectivity to really be able to make progress. FGFR3 biology is implicated both in bladder cancer and in kids with dwarfism and short stature conditions. And there have long been chemical matter drugs that can inhibit FGFR3, but also inhibit close family members, including FGFR1 and 2. These close family members, the nature of the close family members, make it very challenging to make a drug that is a drug candidate that selectively inhibits FGFR3 while sparing FGFR1, 2, and 4."   "And it was a challenge we took on because we felt like we could meaningfully improve the outcomes for patients by doing so. FGFR3 has important biology in bone and cancer, but FGFR1 and 2 have important biology as well and can lead to side effects when inhibited at the same time as FGFR3. So our attempt to make a selective inhibitor is really an effort to minimize off-target tolerability effects, things that can affect, like pain in your nails, blistering of hands and feet, and elevated phosphate levels when taking the pan FGFR drugs. And then just focus on a drug that can inhibit FGFR3, avoid that type of toxicity, and be able to more meaningfully impact these genetic conditions." #TyraBio #TyraBiosciences #PrecisionMedicine #BladderCancer #RareDiseases #Achondroplasia #Biotechnology #DrugDevelopment #FGFR3 #Innovation #ClinicalTrials #Oncology #PediatricMedicine #StructureBasedDrugDesign tyra.bio Download the transcript here 

Todd Harris, CEO and Co-Founder of Tyra Biosciences, is focused on developing a selective inhibitor for FGFR3, a protein implicated in bladder cancer and childhood dwarfism. The company has developed the SNAP discovery platform to accelerate structure-based drug design targeting this specific protein, while avoiding effects on related proteins to minimize significant side effects. Their lead drug candidate has the potential to become a primary well-tolerated oral monotherapy, shifting the treatment paradigm for cancer patients to prevent recurrence and for children to allow for more typical bone growth. Todd explains, "We are taking a novel step to a set of conditions, genetic conditions in FGFR3 biology that have long been known, that others have attempted to address, but where the underlying chemistry hasn't had the necessary selectivity to really be able to make progress. FGFR3 biology is implicated both in bladder cancer and in kids with dwarfism and short stature conditions. And there have long been chemical matter drugs that can inhibit FGFR3, but also inhibit close family members, including FGFR1 and 2. These close family members, the nature of the close family members, make it very challenging to make a drug that is a drug candidate that selectively inhibits FGFR3 while sparing FGFR1, 2, and 4."   "And it was a challenge we took on because we felt like we could meaningfully improve the outcomes for patients by doing so. FGFR3 has important biology in bone and cancer, but FGFR1 and 2 have important biology as well and can lead to side effects when inhibited at the same time as FGFR3. So our attempt to make a selective inhibitor is really an effort to minimize off-target tolerability effects, things that can affect, like pain in your nails, blistering of hands and feet, and elevated phosphate levels when taking the pan FGFR drugs. And then just focus on a drug that can inhibit FGFR3, avoid that type of toxicity, and be able to more meaningfully impact these genetic conditions." #TyraBio #TyraBiosciences #PrecisionMedicine #BladderCancer #RareDiseases #Achondroplasia #Biotechnology #DrugDevelopment #FGFR3 #Innovation #ClinicalTrials #Oncology #PediatricMedicine #StructureBasedDrugDesign tyra.bio Listen to the podcast here 

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/   00:00:00 - Intro - New Teas! 00:15:48 - Weight - Hormones  00:32:34 - Diverticulitis 00:40:55 - Hyperthyroidism 00:47:50 - Bladder Cancer 00:54:58 - Lungs - Mucous - Breathlessness 01:13:43 - Myasthenia Gravis (MG) - Psoriasis - Afib (Atrial Fibrillation) 00:15:48 - Weight - Hormones  Is the extra weight holding back the flow of things? 00:32:34 - Diverticulitis I was told to have colorectal surgery to remove my entire large colon due to the bleeding. 00:40:55 - Hyperthyroidism The day after a vaccine, I started shedding my hair. 00:47:50 - Bladder Cancer Please tell me how I can rid my bladder of the chemo and restore the cells? 00:54:58 - Lungs - Mucous - Breathlessness Could you please talk about fasting one's way into a breatharian lifestyle? 01:13:43 - Myasthenia Gravis (MG) - Psoriasis - Afib (Atrial Fibrillation) I'm a MD from Mexico, living for a long time in the United States.

Broadcast from KSQD, Santa Cruz on 1-08-2026: Dr. Dawn concludes her 2025 medical advances recap, noting that while GLP-1 weight loss drugs showed unexpected benefits for addiction, schizophrenia, and dementia risk, Novo Nordisk recently reported semaglutide had no effect on cognition in people with existing dementia or mild cognitive impairment. She describes the first successful human bladder transplant performed on May 4th. The 41-year-old recipient received both kidney and bladder due to the bladder's complex blood vessel network. Surgeons practiced on cadavers with active circulation before achieving success, opening pathways for future bladder-only transplants for the 84,000 Americans diagnosed with bladder cancer annually. An emailer follows up about purslane for cognitive health. Dr. Dawn reviewed the referenced studies and found neither actually supported claims about purslane and cognition—one discussed the Lyon Heart Study's Mediterranean diet, the other described antioxidant properties. She cautions listeners that websites citing "scientifically proven" claims often reference articles that don't support their assertions. An emailer asks about statin alternatives after developing severe muscle pain on both atorvastatin and rosuvastatin. Dr. Dawn suggests he shouldn't be on statins given his classic adverse reaction. She recommends ezetimibe plus oat bran for cholesterol, metformin for his elevated triglycerides indicating insulin resistance, and checking LDL particle size and inflammation markers. She emphasizes that cholesterol is a risk factor, not a disease, and treating 50 low-risk people for 10 years prevents only one heart attack. A caller discusses plaque formation theory, comparing it to calluses. Dr. Dawn explains Linus Pauling's similar hypothesis that plaque forms at vessel bifurcations to protect against turbulent blood flow damage. She warns against driving total cholesterol below 130, as it disrupts steroid hormone production. The caller shares his mother's near-fatal rhabdomyolysis from statins—muscle breakdown releasing myoglobin that clogs kidneys—and criticizes data transfer failures between hospital systems. An emailer reports four UTIs in two months at age 79. Dr. Dawn questions whether all were true infections, since vaginal contamination causes false positives on dipstick tests. For confirmed UTIs, she recommends D-mannose and cranberry to prevent bacterial adhesion, post-void residual ultrasound to check for incomplete emptying, lactobacillus probiotics, and vaginal DHEA (Intrarosa) to restore mucosal thickness and disease resistance. Dr. Dawn describes Stanford's Phase III trial for dystrophic epidermolysis bullosa, where defective collagen-7 causes skin layers to separate at the slightest touch. Researchers take patient skin biopsies, use retroviruses to insert corrected genes, grow credit-card-sized skin grafts over 25 days, then suture them onto wounds. At 48 weeks, 65% of treated wounds fully healed versus 7% of controls. She reports a Stanford study showing premature babies who heard recordings of their mothers reading for 2 hours 40 minutes daily developed more mature white matter in language pathways. The left arcuate fasciculus showed greater development than controls, demonstrating how early auditory stimulation shapes brain circuitry even in NICU settings. Dr. Dawn concludes with tattoo safety concerns. Modern vivid inks contain compounds developed for car paint and printer toner, including azo dyes that break down into carcinogenic aromatic amines—especially during laser removal. Pigment particles migrate to lymph nodes and persist in macrophages, causing prolonged inflammation. She advises those with tattoos to avoid laser removal, wear sunscreen, practice lymphatic hygiene, and reconsider extensive new tattoos.

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included: • Overview of the Keynote-905/EV-303 study and its significance • Comparison with previous studies like the NIAGARA trial • Discussion on the side effects of EV Pembro and management strategies • The role of ctDNA in guiding post-operative therapy • Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology! #BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

The Holiday Season in NYCPeanut allergies cause and effectWhich calcium supplements can I take if I'm allergic to cow protein?Can my husband take saw palmetto in lieu of his prostate medications?What do you think of traction to help bulging discs?What is your take on green powder supplements?

What do you think of serrapeptase for reducing coronary plaque?We were told to get a TDAP vaccine or we wouldn't be able to see our new grandchild for 8 weeks!Do I have lupus?Which supplements tend to reduce negative effects of X-rays?

Tom, Brian and Silke discuss the blockbuster 2025 for urothelial cancer

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics: Introduction (0:00) Prostate Cancer (1:44) Urothelial Bladder Cancer (29:18) CME information and select publications

Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here.

Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

Can genomic classifiers close the gap between what we see and what a tumor will do? In this episode of BackTable Urology, Dr. Carissa Chu (UCSF) joins Dr. Ruchika Talwar (Vanderbilt) to explore how genomic classifiers are reshaping the way clinicians diagnose and manage bladder cancer. --- This podcast is supported by: VeracyteVeracyte.com/decipher-bladder --- SYNPOSIS They discuss the limitations of traditional staging systems and how molecular subtyping is providing deeper insight into tumor biology, treatment response, and prognosis. Dr. Chu highlights where these classifiers can be integrated into real-world clinical decision-making today, where the evidence is still emerging, and which ongoing trials may define the next era of precision medicine in urologic oncology. --- TIMESTAMPS 0:00 - Introduction3:01 - Overview of Genomic Classifiers9:34 - Risk Stratification15:22 - Current Evidence for Genomic Classifiers22:07 - Clinical Implications of Biomarkers27:23 - Ordering Genomic Classifiers33:46 - Future Directions37:57 - Final Takeaways --- RESOURCES Alignment of molecular subtypes across multiple bladder cancer subtyping classifiershttps://pubmed.ncbi.nlm.nih.gov/38480079/ GUSTO Trialhttps://fundingawards.nihr.ac.uk/award/NIHR128103

In this plain language podcast, the authors discuss highlights from the American Urological Association (AUA) Annual Meeting 2025. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of bladder cancer. This podcast is intended to broaden the reach of complex data and insights from AUA 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors introduce the current treatment landscape for patients and discuss four clinical trials focusing on patients with bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC). This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00409-4. All conflicts of interest can be found online. This podcast is primarily intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Send us a textMorning Prayer (Humility; prostate & bladder cancer; breast & uterine cancer; pre-believers) #prayer #morningprayer #pray #jesus #god #holyspirit #aimingforjesus #healing #peace #love #bible #prebelievers #cancer #humble #hymility #uterinecancer #breastcancer #prostatecancer #bladdercancer Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

This EAUN edition of EAU Podcasts presents the latest update of the intravesical instillation guidelines, featuring insights from experts Bente Thoft Jensen RN, PhD, Susanne Vahr Lauridsen RN, PhD, and Lisbeth Leinum RN, PhD.They discuss the key recommendations and changes since the previous version, as well as the impact on clinical practice, and how nurses and patients benefit from the guidelines. They also outline the evidence-based development process of the guidelines and highlight the focus on nurse and patient safety, education, risk stratification and management of complications. The speakers emphasise growing evidence on managing side effects and the increasing attention to patient perspectives and quality of life.A key message is the importance of improving patient adherence and ensuring nurses understand the differences between BCG and Mitomycin to maintain safety.-----Host: Lisbeth Leinum, EAUN board memberSpeakers: Bente Thoft Jensen, RN, senior researcher, chair of the Bladder Cancer SIG and the guideline panel; Susanne Vahr Lauridsen, RN, senior researcher, member of the guidelines panel.-----For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Matt Galsky joins to discuss the latest iteration of the Uromigos Score in Bladder Cancer. This score quantifies the clinical value of various approaches across several disease states. 30 global experts score each approach.

In November 2019, Margo Wickersham noticed blood in her urine.  Three months later, she was diagnosed with two types of bladder cancer.  After an aggressive chemotherapy regimen, she underwent a radical cystectomy and a hysterectomy in June 2020, resulting in the removal of her bladder, uterus and ovaries, all this during the quarantine phase of the COVID pandemic.   Ever since, Margo has been cancer-free, but she had to get fitted with a stoma bag and had to learn how to manage it.  The bag is an annoyance, but she considers it a small price to pay in order to stay alive.   When Margo first noticed blood in her urine, she sought medical attention, thinking she had a urinary tract infection.  It turned out she didn't have a UTI, but she still thought something was wrong.  She underwent a cystoscopy, which captured a photo of a cauliflower-shaped tumor in her bladder.  Next up was a biopsy, which indicated she had Stage One bladder cancer.  Her urologist prescribed BCG immunotherapy.   Margo sought a second opinion and her doctor ruled out BCG, because further probing turned up a second type of bladder cancer, plasmacytoid, and said it could not be addressed with BCG.  He called for an aggressive chemotherapy regimen.  He also said in addition to a radical cystectomy, which would remove Margo's bladder, he said a hysterectomy would be necessary, a procedure that would remove her uterus and ovaries.   Both were performed in June 2020.  Because that was during the quarantine phase of the COVID pandemic, neither Margo's husband nor members of her family could visit her.   After the procedures, Margo was cancer-free.  However, her life would never be the same after she had to wear a stoma bag into which her urine would go.  Sometimes the bag leaks when filled beyond its capacity.  She accepts this as her new normal and says she can deal with it, but has to think ahead in terms of access to a bathroom.   By way of advice, Margo says one's primary emotion should be that of hope and not stress.   Additional Resources:   Support Group:   Bladder Cancer Advocacy Network  https://www.bcan.org   Margo's Book, available on Amazon and Kindle:  Gratitude in the Storm – When Not Dying Is Enough to Keep Fighting   Margo's merchandise line: www.ThriverSurvivor.shop, with a portion of the revenue going to the Bladder Cancer Advocacy Network, to fund bladder cancer research

In this special 20th-anniversary episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with leading urologic oncologist Dr. Sia Daneshmand to explore a new bladder cancer therapy: Johnson & Johnson's newly FDA-approved INLEXZO™. Dr. Daneshmand—who helped lead its clinical trials—breaks down how this "pretzel-shaped" intravesical delivery system works, why it's showing some of the highest response rates yet for BCG-unresponsive disease and what patients can realistically expect in terms of side effects, treatment schedule, and quality of life. Together, they discuss the future of drug-delivery technology in bladder cancer and why this moment can offer hope to bladder cancer patients.

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer. Key topics included: The definition and characteristics of high-risk non-muscle invasive bladder cancer. Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment. The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach. Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy. Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes. Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology! #NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. In the final part of this 3-part series, Dr Terris discussed how the early diagnosis of bladder cancer presents a significant challenge, particularly in female patients, who are frequently diagnosed at a later stage of the disease and subsequently respond less favorably to treatment modalities. A crucial component of early detection is the rigorous evaluation of hematuria, she emphasized. Microhematuria is defined strictly by microscopy. Reliance solely on a dipstick test is insufficient; any positive dipstick result necessitates a microscopic examination, she explained. Furthermore, patients currently receiving anticoagulation therapy do not bypass the standard workup, she noted. If hematuria is identified alongside a urinary tract infection or gynecological issue, the urine should be rechecked once the co-existing problem has cleared, she advised. Risk assessment must consider both common and less-recognized factors, particularly in women, according to Terris. Standard risks include exposure to cyclophosphamide or ifosfamide, Lynch syndrome, chronic indwelling Foley catheters, benzene/aromatic amine exposure, and smoking, she added. However, uro-oncologists must actively assess female patients for occupational exposures not traditionally associated with bladder cancer, she said. Patients presenting with microhematuria should be stratified into low-, intermediate-, or high-risk groups, Terris continued. The gold standard evaluation for high-risk patients is a cystoscopy and CT urogram, she reported. The CT urogram involves cross-sectional imaging of the abdomen and pelvis with and without contrast, incorporating delayed images to optimally visualize the renal pelvis and ureters for potential filling defects, she noted. If patients cannot tolerate contrast, an MR urogram is the primary alternative, she stated. If neither CT nor MR urogram can be performed, the default workup is non-contrast CT combined with cystoscopy and retrograde pyelograms, although this requires general anesthesia, she explained. Given that women are often diagnosed with bladder cancer late and face poor outcomes with advanced disease, maintaining a heightened awareness and low threshold for investigation is critical, Terris concluded.

With the right protocols (and the right team!), urology clinics can proactively manage the side effects of intravesical therapy. This in-studio episode from the 2025 NMIBC Creator Weekend™ series features unique perspectives from Vanderbilt nurse practitioner Meredith Donahue and surgical neuro-oncology nurse Brynn Moore, a surgical neuro-oncology nurse, both with focuses in urologic oncology. Hosted by Dr. Ruchika Talwar, we cover the practical and logistical considerations in intravesical therapy administration. --- This podcast is supported by: Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/ --- SYNPOSIS Donahue and Moore share their experiences with intravesical therapy, discussing practical issues such as patient management, scheduling, and handling side effects. They emphasize the importance of creating a supportive environment in clinics, proactive treatment plans, and ensuring effective communication among the multidisciplinary team. They also share resources and tips for nurses and nurse practitioners new to urologic oncology. --- TIMESTAMPS 00:00 - Introduction07:09 - Multidisciplinary Team Dynamics11:34 - Resources for Patients18:55 - Transvaginal Estrogen Cream26:56 - Optimizing Intravesical Therapy Clinics35:57 - The Importance of Multidisciplinary Collaboration36:27 - Conclusion

In this episode of AUANews Inside Tract, join Dr. Kyle A. Richards and Dr. Kathryn Marchetti as they celebrate Bladder Health Month by talking about innovations in bladder cancer. In this conversation, they explore the rapidly evolving landscape of non–muscle invasive bladder cancer (NMIBC) — from FDA-approved advances like ZUSDURI (mitomycin gel) to emerging chemoablation therapies, the BCG shortage, and the promise of gene-based treatments for BCG-unresponsive disease. This episode is supported by Natera.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. In part 2 of this 3-part series, Dr Terris discussed the disparities in treatment and outcomes for women with bladder cancer. Although bladder cancer is less common in females than in males, female patients tend to have significantly worse outcomes, Terris explained. Delayed diagnosis is a contributing factor, but the exact reasons for the poorer prognosis are not fully understood, she emphasized. Treatment difficulties begin surgically, according to Terris. From a surgical perspective, she noted that, performing a cystectomy on a woman is more challenging due to factors like pelvic varicosities and differing fat distribution, which complicate stoma creation. In terms of medical treatment, Terris also explained that women exhibit worse tolerability and higher rates of discontinuation of immunotherapy, and that they often experience poor efficacy outcomes regardless of whether they complete the course of treatment. These differences between men and women may be linked to factors such as hormonal influences or antibody introduction during pregnancy. Conversely, classic cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy have been shown to have similar overall survival and disease-free survival in eligible female and male patients. Biologically, Terris also reported that tumors in women may exhibit more effective immune escape mechanisms, possibly connected to differences in the bladder microbiome. The presence of bacteria in bladder tumors has been found to be enriched in patients who did not respond to neoadjuvant chemotherapy, which is relevant as women are more prone to bladder colonization, she added. Overall, Terris emphasized that oncologists must be aggressive in treating women with bladder cancer, despite surgical complexities, and highlighted that early detection is key.

As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC). --- This podcast is supported by: Ferring Pharmaceuticals https://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/ --- SYNPOSIS The conversation covers the current challenges of interpreting positive biomarkers without clinical correlates, the gold standard of biopsies, and the potential of various biomarkers such as urine cytology, FISH, and newer genomic tests like the Decipher Bladder Genomic Classifier. They also touch upon the role of AI in pathology, the cost implications of biomarkers, and how these tools might influence future clinical practices and patient decisions. The episode emphasizes the need for precision medicine, careful patient counseling, and the impact of false positives and negatives on both patients and healthcare providers. --- TIMESTAMPS 00:00 - Introduction05:25 - Challenges with Current Biomarkers08:10 - New Biomarkers and Genomic Classifiers21:10 - AI and Pathology in Bladder Cancer35:13 - Screening and Future Directions41:20 - Challenges and Future Directions in Bladder Cancer Surveillance57:51 - Conclusion --- RESOURCES DaBlaCa-15 Trialhttps://pubmed.ncbi.nlm.nih.gov/40280776/ Sam Chang CHAI Studyhttps://pubmed.ncbi.nlm.nih.gov/40514253/

Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.

Send us a textWelcome to The Oncology Journal Club Podcast Series 3Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology NetworkKate Clarke takes over hosting duties!Join our expert trio — Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson — for the usual OJC antics in Part 2 of our ESMO Special.Craig talks us through the GU and lung highlights, while the team each share their top ‘practice-changing' abstracts. Plus, CJ chats with Susie Stanway about the upcoming London Global Cancer Week.Expect nuanced analysis, sharp insights and the occasional cheeky joke along the way.To learn more about The Oncology Network, subscribe to our free weekly Newsletter and listen to other fantastic podcasts, visit our website: www.oncologynetwork.com.au. You'll also find the Show Notes on the website with links to the abstracts, bios of our hosts and a downloadable Bingo Card

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University.  In part 1 of this 3-part series, Dr Terris discussed the prevalence of bladder cancer in women, as well as reasons for diagnostic disparities that contribute to poor treatment outcomes. She noted that this disease is often diagnosed at later stages in women than in men, often resulting in diagnoses of more advanced disease and translating to poorer outcomes. She added that although female patients represent a minority of those with urothelial carcinoma, retrospective data indicate that women tend to be diagnosed at later stages and consequently experience worse survival rates, regardless of the disease stage. Dr Terris identified several theories explaining why this diagnosis delay occurs. One possible reason is patient-related: women may be less likely than men to consult a physician when they notice blood in their urine because they may be conditioned to dismiss blood if they experience menstrual bleeding. However, physician behavior and bias also contribute to diagnostic disparities, Terris said. Women with suspected hematuria typically receive fewer imaging tests, she continued. Additionally, physicians may be biased, attributing hematuria to uterine bleeding, menstruation, or other benign causes.  Overall, Terris emphasized that early detection is key. If there is any suspicion of a malignancy, patients should be referred directly to a urologist, she stated. Urologists should be willing to work up cases that might ultimately be recurrent urinary tract infections or radiation cystitis to avoid undiagnosed cases of bladder cancer in women, she concluded.

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.

Send us a textUrologist Dr. Yaw Nyame joins Dr. Michael Koren to discuss bladder and prostate cancers. Dr. Nyame talks about his journey through college - including the choice between rock stardom and medical school - and how he got to the Fred Hutch Cancer Center in Seattle. Dr. Nyame explains symptoms, the history, and treatments for prostate and bladder cancer. He tells us "if you have blood in the urine, you definitely want to get to your primary care doctor." He also expands on gaps in cancer outcomes for Black men. Along the way, we weigh benefits and harms of PSA screening and talk honestly about sexual health after treatment.Show Note: Lynch syndrome is a genetic condition also known as hereditary nonpolyposis colorectal cancer (HNPCC). It represents an increased risk of several cancers, including colorectal, endometrial, gastric, ovarian, and pancreatic cancer. It is caused by an error in the DNA mismatch repair mechanism, which normally corrects for random insertions into the DNA code.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review ESMO 2025's bladder cancer headlines, from the evolving role of PD-1/PD-L1 inhibitors to ctDNA-guided adjuvant therapy and antibody-drug conjugates redefining metastatic management.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Morgan Roupret (FR), on the results of the ALBAN trial. A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG naïve high-risk, non-muscle invasive bladder cancer.This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Nicholas James (GB) on the results of the final survival analysis from the BladderPath trial, a randomised comparison of upfront magnetic resonance imaging versus transurethral resection for staging new bladder cancers. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who's on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.---TIMESTAMPS00:00 - Introduction02:04 - The Role of Medical Oncologists in Bladder Cancer12:58 - Combination Therapies and Patient Outcomes21:18 - The CREST Study26:59 - Managing Adverse Events34:44 - Collaboration Between Urologists and Oncologists41:06 - Conclusion and Final Thoughts---RESOURCESCREST Trialhttps://www.nature.com/articles/s41591-025-03738-zCISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Prof. Maria De Santis (DE) about the result of the final analysis of the phase III, open-label, randomised POTOMAC trial: Durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Christof Vulsteke (BE) on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with Dr. Mark Schoenberg—renowned urologist and Chief Medical Officer at UroGen® Pharma—for a wide-ranging conversation about the evolution of bladder cancer research, treatment, and patient advocacy. Dr. Schoenberg shares the story behind BCAN's founding, the early challenges of raising awareness, and the innovations that are reshaping care today, including the development of non-surgical therapies like ZUSDURI™ (mitomycin) for intravesical solution, a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove the tumor and it did not work or is no longer working. From his decades of patient-centered work to his role in pioneering new approaches with UroGen, Dr. Schoenberg offers insights into where the field has been and the promising future ahead. Tune in to hear a fascinating mix of history, science, and hope for patients and families impacted by bladder cancer. Please see the link to the full Prescribing Information on the podcast web page or available at www.zusduri.com.  ZUSDURI Prescribing Information ZUSDURI Patient Information Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove tumor and it did not work or is no longer working. ZUSDURI™ Important Safety Information You should not receive ZUSDURI™ if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI™. Before receiving ZUSDURI™, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI™ can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI™. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI™. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 6 months after the last dose. Males being treated with ZUSDURI™: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI™ passes into your breast milk. Do not breastfeed during treatment with ZUSDURI™ and for 1 week after the last dose. How will I receive ZUSDURI™? You will receive your ZUSDURI™ dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI™ according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI™, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI™: ZUSDURI™ may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI™ include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.  JELMYTO® Important Safety Information You should not receive JELMYTO® if you have a hole or tear (perforation) of your bladder or upper urinary tract. Before receiving JELMYTO®, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant. JELMYTO® can harm your unborn baby. You should not become pregnant during treatment with JELMYTO®. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO®. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO® and for 6 months after the last dose. Males being treated with JELMYTO®: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO® and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if JELMYTO® passes into your breast milk. Do not breastfeed during treatment with JELMYTO® and for 1 week after the last dose. Tell your healthcare provider if you take water pills (diuretic). How will I receive JELMYTO®? Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO® treatment. You will receive your JELMYTO® dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO® according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses. JELMYTO® is given to your kidney through a tube called a catheter. During treatment with JELMYTO®, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving JELMYTO®: JELMYTO® may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. JELMYTO® may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO®. Bone marrow problems. JELMYTO® can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO®. Your healthcare provider may need to temporarily or permanently stop JELMYTO® if you develop bone marrow problems during treatment with JELMYTO®. The most common side effects of JELMYTO® include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please click here for JELMYTO® Full Prescribing Information, including the Patient Information, for additional information.  

This content was funded by AstraZeneca, and is intended for US Healthcare Professionals.   How do urologists, oncologists, and advanced practice providers coordinate care in muscle-invasive bladder cancer (MIBC)?   This AMJ podcast brings together three leading experts in each speciality to explore best practices in MDT collaboration, patient transitions, and treatment strategy.    Listen now to strengthen your approach to MIBC care.    Chapters: 00:00 – 02:18 | Introductions 02:18 – 10:15 | MDT Collaboration & Best Practices 10:15 – 16:16 | Patient Pathway & Coordination 16:16 – 25:23 | Treatment Decisions & Strategy 25:23 – 33:38 | Immune-Mediated AR Management 33:38 – 38:52 | Key Takeaways    Speakers:   Chandler Park, MD – Medical Oncologist, Norton Cancer Institute; & Clinical Faculty, University of Louisville School of Medicine   Gautam Jayram, MD – Urologist, Urology Associates, Nashville, TN   Michael White, PA-C – Physician Assistant, Urology Partners of North Texas

Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

In this powerful episode of Bladder Cancer Matters, host Rick Bangs welcomes Dr. Rick Zera, a retired surgical oncologist who spent decades treating breast cancer before unexpectedly becoming a bladder cancer patient himself. Dr. Zera shares his remarkable story of moving from the operating room to the patient's chair, beginning with a shocking diagnosis of an extremely rare and aggressive bladder cancer. He speaks candidly about the delays and frustrations he faced in getting timely care, the difficult choices between treatment options, and the emotional toll of navigating his own cancer journey after a career spent guiding others through theirs. What follows is an honest, deeply human conversation about risk, resilience, and perspective. Dr. Zera reflects on what he learned about himself, his colleagues, and the vital role of support systems—from family and friends to social workers and fellow patients.

Urologist Fara Bellows discusses her article "When recurrent UTIs might actually be bladder cancer." Fara shares the story of a 91-year-old patient whose recurrent urinary infections masked an underlying bladder cancer diagnosis, illustrating how easily symptoms can be misattributed. She explains risk factors such as smoking, prior radiation, and occupational exposures, and highlights the alarming statistics that nearly 20,000 women will be diagnosed with bladder cancer in 2025, with close to 5,000 deaths. Fara emphasizes the dangers of delayed diagnosis in women due to symptom overlap with common conditions, and she outlines the three key diagnostic tools—urine cytology, imaging, and cystoscopy—that can save lives when used early. Listeners will learn why vigilance in primary care, proactive referrals, and patient advocacy are crucial to ensuring timely and accurate diagnoses. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Bladder Cancer Matters just hit a huge milestone—our 100th episode! In this special 20th anniversary edition of our Partners in Progress series, host Rick Bangs talks with Drew and Erica, whose mom Fran is living with bladder cancer, about what it means to be a caregiver. From music-filled car rides to difficult treatment decisions, they share honest, heartfelt stories of resilience, laughter, hope and the power of family.

Headlines:  – Welcome to Mo News (02:00) – National Chicken Wing Day (02:10) – NYC Mass Shooting (06:30) – Trump Says US Will Set Up Gaza ‘Food Centers' Amid Ongoing Starvation Crisis (12:20) – Sen. Josh Hawley Introduces Bill To Send Tariff Rebate Checks To Americans (21:50) – Trump, Losing Patience With Putin, Says He Will Shorten Deadline to End Ukraine War (27:40) – Ghislaine Maxwell Files Supreme Court Brief Appealing Epstein Conviction (30:45) – Deion Sanders Says He Had Bladder Cancer But Plans to Coach The Colorado Buffaloes This Season (34:00) – Walking Can Reduce the Risk of Alzheimer's, Study Says (36:20) – Goodbye Gentle Parenting, Hello ‘F—Around and Find Out' (38:10) – On This Day In History (45:25) Thanks To Our Sponsors:  – ⁠LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase–⁠ Industrious⁠ - Coworking office. 30% off day pass–⁠ Athletic Greens⁠ – AG1 Powder + 1 year of free Vitamin D & 5 free travel packs– ⁠Incogni⁠ - 60% off an annual plan| Promo Code: MONEWS

Deion Sanders revealed his medical issue, and Ozzy's funeral will be small. Learn more about your ad choices. Visit megaphone.fm/adchoices

NFL legend and Colorado Buffaloes head coach Deion Sanders is officially cancer-free following bladder-removal surgery performed to remove a high-grade tumor. Sanders revealed he drafted his will during the ordeal, describing the journey as emotionally intense. Despite ongoing lifestyle adjustments, Sanders is set to return to coaching this fall and hopes his transparency will raise awareness about early cancer detection. See omnystudio.com/listener for privacy information.

It is Tuesday on The Rickey Smiley Morning Show Podcast and there are a variety of stories the crew discussed today. A tragic mass shooting at 345 Park Avenue—a Midtown Manhattan office building housing the NFL and major finance firms—left five dead, including NYPD officer Didarul Islam, and injured others as the shooter, identified as Las Vegas resident Shane Tamura, took his own life. Authorities found a note suggesting Tamura blamed the NFL for degenerative brain injury (CTE)—though his exact motive remains unclear. In brighter news, NFL legend and Colorado Buffaloes head coach Deion Sanders is officially cancer-free following bladder-removal surgery performed to remove a high-grade tumor. Sanders revealed he drafted his will during the ordeal, describing the journey as emotionally intense. Despite ongoing lifestyle adjustments, Sanders is set to return to coaching this fall and hopes his transparency will raise awareness about early cancer detection. On the entertainment beat, rapper and mogul Jeezy celebrated 20 years of his debut album Thug Motivation 101 during his appearance on The Rickey Smiley Morning Show. He reflects on performing the album with an orchestra and discussing the legacy of the Snowman—tying it into broader conversations about his entrepreneurial evolution and cultural impact. Website: https://www.urban1podcasts.com/rickey-smiley-morning-show See omnystudio.com/listener for privacy information.